Research
Hormonal
Time-restricted eating (TRE) significantly reduces diastolic blood pressure (DBP) in adults with obesity, but does not significantly affect systolic blood pressure (SBP).
If you have high blood pressure, TRE might help lower your diastolic (bottom) number, but don't expect it to significantly change your systolic (top) number. This is a secondary benefit to weight loss, not a primary treatment for hypertension.
GoodQualifiesMEDIUM confidence
The TRE group showed a statistically significant reduction in DBP (−2.26 mmHg; 95% CI [−4.02, −0.50], p = 0.01, I2 = 0%) compared to the control group, however, there was no difference in SBP (−0.75 mmHg; 95% CI [−3.14, 1.63], p = 0.54, I2 = 0%)
Why this rating
Meta-analysis of 5 RCTs, low heterogeneity, but limited number of studies for this specific outcome.
Source
Health effects of the time-restricted eating in adults with obesity: A systematic review and meta-analysis
Wei‐Yi Chen et al. · Frontiers in Nutrition · 2023
DOI 10.3389/fnut.2023.1079250
Meta-analysis · 9 studiesCited 40×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Time-restricted eating (TRE) with an 8-hour daily eating window significantly reduces body weight and fat mass in adults with obesity compared to control groups, particularly when the intervention lasts longer than 12 weeks.Good
- Time-restricted eating (TRE) does not significantly preserve lean body mass compared to control groups in adults with obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →